JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphomaJaroslav Žák, John R. Teijaro, Reza Beheshti Zavareh et al.|Science|2024Cited by 173
Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and EfficacyVeronika Bachanová, Vaishalee P. Kenkre, Livia Hegerova et al.|Blood|2021Cited by 14